Back to Search Start Over

Epidemiological Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Use in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in Terms of Second Line (2L) Treatment: An Ad Hoc Analysis from the POLARIX Study

Details

ISSN :
15280020 and 00064971
Volume :
140
Database :
OpenAIRE
Journal :
Blood
Accession number :
edsair.doi...........d2941544704e7b069d379c5659324426
Full Text :
https://doi.org/10.1182/blood-2022-157904